Revolution Medicines, Inc. (NASDAQ:RVMDW – Get Free Report) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 1,373 shares, a decrease of 29.3% from the November 30th total of 1,943 shares. Based on an average trading volume of 28,634 shares, the days-to-cover ratio is presently 0.0 days. Based on an average trading volume of 28,634 shares, the days-to-cover ratio is presently 0.0 days.
Revolution Medicines Price Performance
Shares of RVMDW stock traded down $0.06 during mid-day trading on Monday, reaching $0.90. The stock had a trading volume of 4,004 shares, compared to its average volume of 30,473. The stock’s 50-day moving average price is $0.62 and its two-hundred day moving average price is $0.38. Revolution Medicines has a 52-week low of $0.03 and a 52-week high of $1.08.
Revolution Medicines Company Profile
Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.
Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.
Recommended Stories
- Five stocks we like better than Revolution Medicines
- Do not delete, read immediately
- How the Rich Retire
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- How Long Will $1M Last in Retirement?
- [No Brainer Gold Play]: “Show me a better investment.”
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
